Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Merus N.V.

Biotech SG&A Expenses: Alnylam vs. Merus

__timestampAlnylam Pharmaceuticals, Inc.Merus N.V.
Wednesday, January 1, 2014445260003852327
Thursday, January 1, 201560610000839656
Friday, January 1, 2016893540004478145
Sunday, January 1, 201719936500016432324
Monday, January 1, 201838235900011890871
Tuesday, January 1, 201947900500034110000
Wednesday, January 1, 202058842000035781000
Friday, January 1, 202162063900040896000
Saturday, January 1, 202277065800052200000
Sunday, January 1, 202379564600059836000
Monday, January 1, 2024975526000
Loading chart...

Igniting the spark of knowledge

Navigating SG&A Expenses: A Tale of Two Biotechs

In the competitive world of biotechnology, effective cost management is crucial for success. Alnylam Pharmaceuticals, Inc. and Merus N.V. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Alnylam's SG&A expenses surged by over 1,600%, reflecting its aggressive growth strategy and expansion efforts. In contrast, Merus N.V. maintained a more conservative approach, with expenses increasing by approximately 1,500% during the same period.

Key Insights

  • Alnylam Pharmaceuticals, Inc.: By 2023, Alnylam's SG&A expenses reached nearly $800 million, a testament to its rapid scaling and market penetration.
  • Merus N.V.: Despite a more modest increase, Merus's expenses grew steadily, peaking at around $60 million in 2023.

These trends highlight the diverse strategies employed by biotech firms in managing operational costs while pursuing innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025